- Khiron High THC medical cannabis product successfully imported
into Peru, with first
prescriptions to be filled in December through a partnership with
Farmacia Universal S.A.C.
- Khiron is the first company to export High THC medical cannabis
from Colombia, and the only
Colombian company authorized to fill High THC prescriptions in
Peru for commercial purposes
- Farmacia Universal operates 10 locations across Lima, a metro region with close to 11 million
residents, representing almost one third of Peru's total population
- Expands on sales in Peru of
Company's High CBD magistral preparations, which began in
September 2020, with month over month
growth in prescriptions filled to date through Farmacia
Universal
- Company to seek expansion of Doctor Zerenia™ digital strategy
in Peru, subject to government
regulatory requirements
- Approximately 100 physicians from Peru have completed Khiron's medical cannabis
diploma program through the Company's partnership with Tecnologico
de Monterrey university in
Mexico
TORONTO, Dec. 10, 2020 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF),
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America and Europe, announced that it has now successfully
completed the import of its High THC medical cannabis product into
Peru, with first prescriptions to
be filled in December.
With today's announcement, Khiron becomes the first company to
export High THC medical cannabis from Colombia and the only Colombian company to
fill High THC prescriptions in Peru for commercial purposes. This expands the
Company's product offering in Peru
where sales of its High CBD product began in September
2020.
"This first shipment of Khiron's trusted High THC product into
Peru represents a first in
exporting High THC medical cannabis from Colombia and delivers on our strategy to
increase our market impact in Peru, providing patients with reliable access
to medical cannabis products. With an established pharmacy partner
and data from medical cannabis prescriptions we have filled to date
in Colombia, we know this will
make a difference in improving the quality of life for patients in
Peru," commented Alvaro Torres, Khiron CEO and Director.
As part of Khiron's Latin
America expansion strategy, its High THC medical cannabis
products were successfully imported into Peru as result of the Company completing all
export, import and distribution requirements, including approved
receipt of quotas for the Company's high THC medical cannabis by
DIGEMID, Peru's drug regulatory
authority. Khiron Peru is a GSP certified, registered
pharmaceutical establishment, and Farmacia Universal has all
required permits and licenses, including Good Manufacturing
Practices (GMP) certification, to prepare magistral preparations
with medical cannabis and distribute final products to patients
through pharmacies under the previously announced agreement with
Khiron.
The Company continues to expand medical cannabis doctor
education, with almost 200 physicians from Peru having obtained their diploma accrediting
completion of Khiron's medical education through the Company's
program with Tecnologico de Monterrey. The Company's high THC
products will focus on helping patients with serious conditions
that include chronic pain, spasticity, PTSD, nausea, insomnia,
anorexia and depression.
About Khiron Life Sciences Corp.
Khiron is a vertically integrated medical and CPG cannabis
company with core operations in Latin
America, and operational activity in Europe and North America. Khiron is the
leading cannabis company in Colombia and the first company licensed in
Colombia for the cultivation,
production, domestic distribution and sales, and international
export of both low and high THC medical cannabis products. The
Company has filled medical cannabis prescriptions in Peru and has a presence in Mexico, Uruguay, UK, Spain and also in Germany, where it is positioned to begin sales
of medical cannabis.
Leveraging its first-mover advantage and patient-oriented
approach, Khiron combines global scientific expertise, product
innovation, agricultural infrastructure, wholly-owned medical
clinics, and online doctor education programs to drive prescription
and brand loyalty to address priority medical conditions. Its
Wellbeing unit launched the first branded CBD skincare brand in
Colombia, with KuidaTM
now marketed in multiple jurisdictions in Latin America, the US and UK. The Company is
led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
@khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-becomes-first-company-to-export-high-thc-medical-cannabis-from-colombia-301190031.html
SOURCE Khiron Life Sciences Corp.